Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Second-line palliative imatinib in advanced bile duct cancer
2005-003166-42Phase 2Terminated
- Sponsor
- Leipzig University
- Start
- Sep 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib in Bile duct adenocarcinoma (CCA) and gallbladder adenocarcinoma, sponsored by Leipzig University. Primary endpoints: Response rate and Median duration of objective remission. Started Sep 2005; status: terminated.
02
Drugs
03
Conditions
Bile duct adenocarcinoma (CCA)gallbladder adenocarcinoma
Beyond the preview
Go deeper on 2005-003166-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003166-42.